Australian biotech market watch 16/10/09
Friday, 16 October, 2009
It looks like the rally experienced by the All Ordinaries this week has finally begun to falter, led by a slip in bank stocks. As of 3pm this afternoon the All Ords was at 4,846, down 16 points for the day.
Heath stock fared a little better, with the S&P/ASX 200 Health Care index rising in the morning and dropping back to its open around 8,509.
Biota Holdings (ASX:BTA) continues its prodigious run, up another 15c today, to $3.42. Just for the record, Biota is up 918% YTD. Makes you think.
Primary Health Care (ASX:PRY) also had a positive day, lifting by 15c, or 2.5%, to $6.25, recovering some of the losses experienced during the week.
Pharmaceutical company, Acrux (ASX:ACR), developers of testosterone deficiency treatment, Axiron, bumped up 5c to $1.83.
ResMed (ASX:RMD) managed to put on 10c to $5.31, up 1.7%, after a week of ups and downs.
Sonic Health Care (ASX:SHL) continued its gains from Thursday, up 1% today to $13.85.
Cochlear (ASX:CHO) remains mainly steady, although a slight afternoon dip as shaved 59c from it stock, to $64.88. Blackmores (ASX:BKL) also shed 0.5% to $21.70.
Healthcare products specialist, Ansell (ASX:ANN), has maintained much of its gains received mid-week after it announced earnings were higher than expected for this quarter, dipping slightly to $10.68 today from its high of $10.95 on Wednesday.
Quitting smoking increases life expectancy even for seniors
Although the benefits of quitting smoking diminish with age, there are still substantial gains...
Stem cell transplants treat blindness in mini pigs
Scientists have successfully transplanted retinas made from stem cells into blind mini pigs,...
Sugary drinks raise cardiovascular disease risk, but occasional sweets don't
Although higher sugar intake raises your risk of certain cardiovascular diseases, consuming sweet...
